Video

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Related Videos
Kathleen N. Moore, MD, MS
Jennifer Scalici, MD
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
5 KOLs are featured in this series.
5 KOLs are featured in this series.